Pressmeddelanden, rapporter och bolagsmeddelande för Eevia Health Plc

Eevia Health PLC has received sales orders totaling 54,000 euros from European and Asian customers following the BIOFACH 2025 trade fair. The orders include products such as Feno-Myrtillus™ 36 and Fenoprolic™ Full Spectrum from German customers, a tart cherry extract from Australia, and Feno-Myrtillus 25 from Taiwan. Eevia has the products in stock, allowing for immediate delivery, which is beneficial for cash flow. These are repeat orders, with expectations for further orders from these customers. Eevia Health, established in 2017, produces bioactive plant extracts for global dietary supplements and food brands, focusing on sustainable and environmentally friendly practices. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc will participate in BIOFACH, a leading trade fair for organic food, from February 11 to 14 in Nuremberg, Germany. The company will promote its organic products in collaboration with its distribution partner BREKO in the DACH countries. Eevia Health, founded in 2017, produces bioactive compounds from renewable plant materials, focusing on gut and related health areas. Their extracts, primarily sourced from Finnish and Swedish forests, are used in dietary supplements and food brands globally. Eevia operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.

Eevia Health Plc has concluded mandatory cooperation negotiations concerning organizational restructuring and downsizing. The company, which employs 19 people, is reducing its workforce: six employees will leave voluntarily (two resigning and four moving to new roles linked to divested assets), two will shift to part-time, and four employment contracts will be terminated. Eevia will retain nine key employees, with expected annual salary savings of KEUR 490. The changes, effective starting February 2025, are intended to improve cost efficiency. They are expected to positively affect operating costs as early as Q1 2024. Despite the reduced staff size, Eevia aims to maintain the core competencies necessary to reach its 2025 revenue target of MEUR 3 and to scale up as future growth opportunities arise. Based on its updated strategy, Eevia will focus on developing proanthocyanidin-based gut health solutions. This shift will result in a different staffing profile, placing greater emphasis on sales, marketing, and product management. Downsizing is intended to restore profitability and align the workforce with Eevia’s business goals, while laying a foundation for growth through scientifically supported botanical solutions. Eevia, founded in 2017, specializes in producing organically certified plant extracts from sustainably harvested materials gathered near or above the Arctic Circle. It supplies these extracts globally for use in dietary supplements and foods, and also develops high-value ingredients and blended solutions. Eevia’s environmentally conscious approach includes a modern production facility and a short value chain. Its shares are listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Eevia Health is hosting two digital investor webinars to provide updates on its strategic reorientation and current rights issue. These webinars are scheduled for February 10 and February 14, 2025, and will be conducted via Microsoft Teams. The sessions will be led by CEO Stein Ulve, CTO Petri Lackman, and Commercial Director Erik Eide. Eevia Health, founded in 2017, focuses on producing bioactive compounds from renewable plant materials for global health challenges, specifically targeting gut, kidney, and urinary health. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.

Eevia Health Plc has agreed to sell the intellectual property related to its lead eye-health compound, Retinari™, to Havu Health Oy for KEUR 800. Retinari™, derived from pine wood, has shown promising pre-clinical results in combating Age-related Macular Degeneration (AMD), a leading cause of blindness. Despite strong interest and top scores in international funding competitions, Eevia did not secure necessary funding for human safety studies, limiting the project's progression. Consequently, the inventors, including Eevia's CTO Petri Lackman, sought commercialization rights outside Eevia. Eevia agreed to sell the intellectual property to Havu Health Oy, a startup founded by Lackman, which plans to commercialize the product and seek development funding. Eevia will receive shares in Havu Health Oy as payment. The transaction is subject to third-party assessment and creditor consent. Eevia Health focuses on bioactive compounds from renewable plant materials and operates a green-chemistry facility in Finland.

Eevia Health Plc has announced that the publication of its Q4 2024 interim report will be moved up to February 4, 2025, from the originally scheduled date of February 14, 2025. This change aims to allow insiders, who are currently restricted by a trading ban, to participate in the ongoing rights issue. As a result, the subscription period for the rights issue has been extended by one week to give investors more time to consider their investments. The updated timetable for the rights issue includes specific trading and subscription periods for Sweden and Finland. Eevia Health, founded in 2017, produces bioactive compounds from renewable plant materials and operates a green-chemistry production facility in Finland. The company's shares are listed on the Spotlight Stock Market in Sweden. The press release emphasizes that it does not constitute an offer to trade securities in jurisdictions where such actions would violate laws and highlights that no prospectus will be prepared for the rights issue.

Eevia Health PLC has announced a strategic reorientation and a rights issue of shares totaling approximately SEK 12.1 million, as decided by the board on January 17, 2025. An investment teaser detailing the company's business, products, strategy, and the rights issue is available on Eevia Health's website. The rights issue will involve trading in subscription rights from January 28 to February 6, 2025, with subscription periods in Sweden and Finland from January 28 to February 11 and January 29 to February 13, respectively. The estimated date for announcing the outcome of the rights issue is February 17, 2025. Eevia Health, founded in 2017, focuses on developing bioactive compounds from renewable plant materials for health areas such as gut, kidney, and urinary health. The company's plant extracts are sold globally as ingredients to dietary supplements and food brands. Eevia Health operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or contact CEO Stein Ulve.

Eevia Health Plc has initiated a rights issue to raise approximately SEK 12.1 million, with the subscription period running from 28 January to 11 February 2025 in Sweden and 29 January to 13 February 2025 in Finland. The rights issue offers existing shareholders preferential rights to subscribe to new shares, with a subscription price of SEK 0.09 per share. The company aims to use the funds to repay debt, support working capital, and invest in product research and development. The rights issue is part of a broader strategic plan, including product diversification towards gut, kidney, and urinary health, and divestments of certain assets to new start-ups, Havu Health Oy and Baccus Salas Oy. These divestments aim to streamline operations and focus on higher-margin, scientifically substantiated products. Eevia is also negotiating with creditors to extend debt maturity and stabilize its financial position. The company plans to continue as a specialized provider of bioactive compounds, targeting global health challenges.

Eevia Health PLC has announced the publication of an exemption document related to a rights issue of shares valued at approximately SEK 12.1 million, as decided by the board on January 17, 2025. This document complies with the EU Prospectus Regulation and has been registered with the Finnish Financial Supervisory Authority. Eevia Health, founded in 2017, focuses on producing bioactive compounds from renewable plant materials for health-related applications. The company operates in Finland, utilizing sustainable practices, and sells its plant extracts globally. Eevia's shares are listed on the Spotlight Stock Market in Sweden. For more information, visit their website or contact CEO Stein Ulve.

Eevia Health has received a sales order worth KSEK 638 / KUSD 59 for its organically certified elderberry extract, Feno-Sambucus™ 7 ORGANIC, from a US customer through Select Ingredients, a company based in San Diego, California. The end customer is a young brand owner in the organic supplements and health products sector. The extract is noted for its high bioactivity performance and contains more polyphenols than comparable products. The order is valued at KEUR 56 and is a repeat order. Eevia Health, founded in 2017, focuses on sustainably extracted bioactive compounds for health, operating a green-chemistry production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.